Dual antiplatelet therapy following coronary stent implantation is associated with improved outcomes

Emmanouil S. Brilakis, M.D., Ph.D., of the VA North Texas Health Care System and University of Texas Southwestern Medical Center at Dallas, and colleagues conducted a review of medical literature regarding optimal medical therapy after percutaneous coronary intervention (PCI; procedures such as balloon angioplasty or stent placement used to open narrowed coronary arteries). The researchers identified 91 studies for inclusion in the review.

"Percutaneous coronary intervention is commonly performed for in patients with stable angina or (ACS), with approximately 600,000 procedures performed in the United States during 2009," according to background information in the article. Stents are currently used in more than 90 percent of patients undergoing PCI because they significantly improve procedural success and subsequent clinical outcomes. The main complications after stent implantation are in-stent restenosis (renarrowing) and stent thrombosis (formation of a blood clot). "The goal of medical treatment after coronary stenting is to prevent stent thrombosis, slow the progression of , and prevent major adverse cardiac events."

The researchers found that dual antiplatelet therapy with aspirin and a P2Y12 inhibitor (e.g., ticlopidine, clopidogrel, prasugref, ticagrelor) is associated with significant improvement in the outcomes of patients undergoing coronary stenting and remains the main medical therapy for optimizing stent-related outcomes after PCI and stent placement. Aspirin should be continued indefinitely and low dose (75-100 mg daily) is preferred over higher doses. A P2Y12 inhibitor should be administered for 12 months after PCI unless the patient is at high risk for bleeding.

"Several ongoing studies will allow further optimization of the medical management of patients who receive coronary stents."

More information: JAMA. 2013;310[2]:189-198

add to favorites email to friend print save as pdf

Related Stories

New anti-clotting drug more effective than current treatment

Mar 11, 2013

A new and experimental anti-clotting drug, cangrelor, proved better than the commonly used clopidogrel and was significantly more effective at preventing blood clots in a large trial of patients who underwent coronary stent ...

Recommended for you

Gene variant raises risk for aortic tear and rupture

17 hours ago

Researchers from Yale School of Medicine and Celera Diagnostics have confirmed the significance of a genetic variant that substantially increases the risk of a frequently fatal thoracic aortic dissection or full rupture. ...

Considerable variation in CT use in ischemic stroke

17 hours ago

(HealthDay)—For patients with ischemic stroke there is considerable variation in the rates of high-intensity computed tomography (CT) use, according to a study published online April 8 in Circulation: Ca ...

Beating the clock for ischemic stroke sufferers

Apr 17, 2014

A ground-breaking computer technology raises hope for people struck by ischemic stroke, which is a very common kind of stroke accounting for over 80 per cent of overall stroke cases. Developed by research experts at The Hong ...

Risk for nonelective thoracic aortic sx up for uninsured

Apr 16, 2014

(HealthDay)—Uninsured patients have an increased risk of nonelective thoracic aortic operations, and have increased risks of major morbidity or mortality, according to a study published online April 8 in ...

User comments